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Abstract The coagulation system contributes greatly to the
evolution ofmyocardial infarction (MI).Anticoagulationmay
reduce the occurrence of MI as monotherapy or with con-
comitant use of aspirin. Activated factor X antagonists (anti-
Xa) and direct thrombin inhibitors have promising results in
various indications in non-inferiority trials. However, results
regarding their cardiovascular safety are heterogeneous. We
systematically evaluated the risk of MI and mortality in
patients receiving the new-generation oral anti-Xa agent
apixaban. Electronic databases were searched to find pro-
spective, randomized, controlled clinical trials (RCT) that
evaluated the clinical impact of apixaban. Efficacy measures
included frequency of MI, cardiovascular and overall mor-
tality. Outcome parameters of RCTs were pooled with a ran-
dom-effects model. Between January 2000 and December
2013, 12 RCTs comprising 54,054 patients were identified.
Based on the pooled results, therewas no increase in the riskof
MI in patients treated with apixaban [odds ratio (OR) 0.90;
95 % confidence interval (CI) 0.77–1.05; p = 0.17] com-
pared to different controls. Cardiovascular and overall mor-
talitywith apixabanwas comparable to the control groups (OR
0.88; 95 % CI 0.72–1.06; p = 0.18, OR 0.89; 95 % CI
0.77–1.03; p = 0.11, respectively). The pooled risk of major
bleeding was lower in the apixaban treated groups (OR 0.84;
95 % CI 0.62–1.12; p = 0.23) however this reached signifi-
cant level only in subgroup analysis of trials with anticoagu-
lant regimes in the control (OR 0.66; 95 % CI 0.51–0.87;
p = 0.003). In a broad spectrum of patients and compared to
different controls apixaban treatment was not associated with
an increase in MI or mortality.
Keywords Myocardial infarction  Apixaban 
Meta-analysis
Introduction
The coagulation system contributes greatly to the evolution
of myocardial infarction (MI). Antiplatelet therapy plays an
essential role in preventing ischemic events among patients
undergoing percutaneous coronary intervention (PCI) and
after acute coronary syndromes (ACS) [1]. However,
thrombotic events in ACS are not completely platelet-
dependent and previous experience with warfarin sug-
gested an incremental ischemic benefit when anticoagula-
tion was applied in combination to aspirin [2]. Though the
high rates of bleeding complications, the narrow thera-
peutic window with need for careful monitoring in addition
to the frequent drug and food interactions offset the
thrombotic benefits and questioned the clinical relevance of
this approach. Novel oral anticoagulants (NOAC) includ-
ing activated factor X antagonists (anti-Xa) and direct
thrombin inhibitors have promising results in various
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indications in multiple non-inferiority trials. However,
heterogeneous results were found regarding their cardio-
vascular safety. Specifically, analyses of trials that tested
NOACs in various indications showed a signal for
increased risk of MI with dabigatran but not with riva-
roxaban [3, 4]. Apixaban is a highly selective, direct
inhibitor of activated factor X that, based on the results of
multiple trials in wide range of indications, became a
promising alternative to vitamin K antagonists.
We therefore performed a systematic review and meta-
analysis and evaluated the risk of MI and mortality in
patients receiving apixaban.
Methods
Study inclusion criteria, endpoints
Our meta-analysis followed the preferred reporting items
for systematic reviews and meta-analyses (PRISMA)
statement [5].
The main criteria for inclusion in the analysis were to
compare the clinical efficacy and/or safety of an antico-
agulant protocol with apixaban in a prospective, random-
ized controlled clinical trial.
PubMed, www.clinicaltrials.gov and Scopus databases
were searched for relevant articles published between
January 2000 and December 2013 using a search strategy
that combined text word and MeSH heading. The search
string was ‘‘apixaban’’ OR ‘‘bms 562247’’ AND ‘‘((ran-
domized clinical trial OR RCT)’’ OR ‘‘(myocardial
infarction OR mortality))’’. Furthermore, we increased the
search with the reference lists of the relevant studies and
reviews, editorials, letters, and also relevant abstracts.
Studies that aimed to compare merely the biological
efficacy of the anticoagulant protocol, trials not reporting
the frequency of MI as well as non-randomized studies and
registries were disregarded.
The primary efficacy endpoint of the analysis was the
frequency of MI. Overall mortality and cardiovascular
death were defined as secondary endpoints. As a safety
measure, frequency of major and clinically relevant non-
major bleeding complications has been evaluated. MI,
cardiovascular death and major and clinically relevant non-
major bleeding were defined according to the internal
definitions of the studies. The endpoints of interest were
collected until the longest follow-up available.
Data abstraction and analysis
Manuscript selection and data abstraction were done
independently by three reviewers (AK, AT and AV). Dis-
agreements were resolved by consensus. Statistical analysis
was performed using the Review Manager 5.1.6 (Review
Manager [RevMan] Version 5.1 Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011.)
software.
Considering that the included trials were done in pop-
ulations with different cardiovascular risk and applied
disparate drug doses with dissimilar treatment effects,
resulting in a substantial inter-study variance we prespec-
ified the assessment of the effect sizes with a random effect
model. The reported event frequencies were used to cal-
culate odds ratios with 95 % CI. Heterogeneity was tested
with a Chi square heterogeneity statistic for which a
p\ 0.2 was considered potentially heterogeneous. Con-
sistency was assessed by I2 statistic which describes the
percentage of total variation across studies that is due to
heterogeneity rather than due to chance. Inconsistency was
described as low, moderate, and high, based on I2 values of
25, 50, and 75 %, respectively [6]. Rate control meta-
regression analysis was performed to examine the effect of
the trials background risk for MI to the effect estimate
related to the apixaban action. To study the relevance of
publication bias, funnel plots were constructed plotting the
trial results against their precision. Risk of bias was
assessed by the built-in risk of bias tool of the review
manager program. Prespecified subgroup analyses were
performed among trials with different agents or placebo in
the control arm. Sensitivity analysis was performed with
fixed effect model, between phase 2 or 3 studies and
according to the indication fields and the concomitant
antiplatelet treatment. A p B 0.05 was considered statisti-
cally significant.
Results
Search results and study characteristics
Our search resulted in 212 citations. After the evaluation of
abstracts, 34 potentially appropriate studies were found.
Finally, 12 studies were selected for data extraction and
analysis [7–18] (Online Resource 1). The included trials
were prospective multicenter randomized trials and
involved 54,054 patients. The main characteristics of the
12 trials are listed in Table 1. Enoxaparin and/or warfarin
were the comparator drugs in seven trials [7, 9–11, 15, 17,
18], four trials were placebo controlled [12–14, 16] and
aspirin was the comparator in one trial [8]. Three studies
included patients who required total knee replacement and
one included hip replacement [7, 9, 10, 18]. Two trials
were preformed in patients after deep vein thrombosis
(DVT) and/or pulmonary embolism (PE) [11, 12]. Three
trials investigated stroke prophylaxis in atrial fibrillation
with adjusted-dose warfarin as the comparator [8, 15, 17].
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Three placebo controlled studies included patients after
ACS [13, 14, 16]. Patients with concomitant antiplatelet
therapy were excluded in eight trials. In the three ACS
studies different proportions of patients were included after
a coronary stent implantation and required concomitant use
of dual antiplatelet therapy. In the APPRAISE-1 and
APPRAISE-2 study the frequencies of PCI were 65.9 and
43.8 % in the apixaban treated group and 64.8 and 44.2 %
in the control group, respectively [13, 14]. In the
APPRAISE-J study the frequency of PCI was 100 % in the
apixaban treated group and 98.1 % in the control group.
[16].
Follow-up varied from 12 days to 21.6 months. Com-
pletion of follow-up was greater than 95.7 % in ten trials.
(Table 2). The APPRAISE-2 and the APPRAISE-J trial
were stopped prematurely [13, 16]. All studies were
sponsored by the manufacturers of apixaban (Bristol-Myers
Squibb and Pfizer). All trials were considered to be uni-
formly of high quality and analysis of funnel plots did not
show signs of publication bias (data not shown).
Table 2 Patient and procedural characteristics of the included trials
Study name/first
author (publication
year)
Phase Mean
age
(year)
Male
(%)
Obesity
(%)
DM
(%)
Hypercholesterolaemia
(%)
Hypertension
(%)
Smoking
(%)
Hospitalization
(days)
Lost to
follow-up
(%)
APROPOS
Lassen MR
(2007)
2 66.7/66.6 36/38.7 – – – – – 6/6 –
ADVANCE-1
Lassen MR
(2009)
3 65.9/65.7 37.6/38.2 – – – – – 6.3/6.4 –
APPRAISE-1
Alexander JH
(2009)
2 61/60 76.8/74.3 – 22.1/23.2 – – – – 1.4
ADVANCE-2
Lassen MR
(2010)
3 67/67 29/26 – – 89/88.3 – – 12/12 –
ADVANCE-3
Lassen MR
(2010)
3 60.9/60.6 47.2/46.2 – – – – – 9.3/9.2 4.3
APPRAISE-2
Alexander JH
(2011)
3 67/67 67.4/68.3 – 48.7/47 83/84.2 – – – 1.8
ARISTOTLE
Granger CB
(2011)
3 70/70 64.5/65 – 25/24.9 45/45.1 87.3/87.6 – – 1.1
ARISTOTLE-J
Ogawa S
(2011)
2 69.6/71.7 83.8/81.1 – 25/20.3 – 82.4/85.1 – – –
AVERROES
Connolly SJ
(2011)
3 70/70 59/58 – 19/20 31/31 86/87 – – –
AMPLIFY
Agnelli G
(2013)
3 57.2/56.7 58.3/59.1 19.4/19.2 – – – – – 0.3
AMPLIFY-EXT
Agnelli G
(2013)
3 56.5/57.1 57.8/56.5 27.3/26.4 11.0/11.2 30.5/29.1 39.9/42.9 18.4/19.1 – 2.1
APPRAISE-J
Ogawa H
(2013)
2 64.9/63.9 89.9/80.8 – 34.3/50.0 – – – – 1.3
Hypercholesterolaemia defined as hypercholesterolaemia and statin use
DM diabetes mellitus
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Clinical results
Based on the pooled results of the random-effects model
meta-analysis, apixaban was not associated with higher risk
for MI when tested against different comparators [(OR)
0.90 (95 % CI 0.77–1.05)] (Fig. 1). The cumulative mor-
tality and rate of cardiovascular deaths were lower with
apixaban, however this difference did not reach statistical
significance [OR 0.89; 95 % CI 0.76–1.03 and OR 0.88;
95 % CI 0.72–1.06, respectively] (Fig. 2, Online Resource
2). The pooled risk of major bleeding was lower in the
apixaban treated groups [OR 0.84; 95 % CI 0.62–1.12),
however, this difference reached significant level only in
subgroup analysis of trials with anticoagulant regimes in
the control (OR 0.66; 95 % CI 0.51–0.87; p = 0.003).
(Fig. 3). Rate control meta-regression analysis, however,
did not show relation of background risk and the effect of
apixaban regarding MI (Online Resource 3).
Data regarding the frequency of MI were consistent
and homogenous. Cardiovascular mortality and overall
mortality data showed low inconsistency, while data
regarding major and clinically relevant non-major bleeding
were inconsistent and heterogeneous in the included trials.
Sensitivity analyses did not showed major difference from
the above results. (Table 3).
Discussion
This meta-analysis involving 54,054 patients provides a
comprehensive assessment of the risk of MI with a novel
active X factor oral anticoagulant agent, apixaban in a
broad spectrum of potential indications. The main finding
of the analysis is that apixaban treatment is not associated
with increased risk of MI. In fact, MI rate was numerically,
however not significantly lower (1.22 vs. 1.39 %) among
patients treated with apixaban. Similarly mortality data
showed no increase with apixaban but a non-significant
tendency for benefit. Altogether these data confirm car-
diovascular safety of apixaban.
Fig. 1 Impact of apixaban on the frequency of myocardial infarction. Subgroup analyses were performed according to the randomized
medications applied in the control groups
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Earlier trials in various fields of prevention found anti-
platelet and anticoagulant agents to be effective in pre-
venting MI. However, due to the delicate balance of the
potential benefit and the increased risk of bleeding rec-
ommendations greatly differ in different clinical situations
regarding the use of these medications [1]. Antiplatelet
therapy is essential in preventing ischemic events among
patients undergoing PCI and after ACS, however, coronary
thrombotic events are not completely platelet-dependent.
Administration of warfarin in combination to aspirin in
patients after an acute coronary event resulted in an
incremental ischemic benefit. In a prior meta-analysis,
therapeutic-range anticoagulation with warfarin [interna-
tional ratio (INR) 2–3] was associated with a significant
reduction of ischemic events [OR 0.73 (0.63–0.84),
p\ 0.0001] but triggered an increased risk of major
bleeding [2]. Due to high rates of bleeding complications,
the narrow therapeutic window with need for careful
monitoring in addition to the frequent drug and food
interactions, however, offset the thrombotic benefits and
questioned the clinical relevance of routine combined
therapy.
Recently, novel agents targeting the thrombin dependent
anticoagulation pathways have emerged and multiple
studies demonstrated their efficacy and better safety profile
in various fields of thromboembolic prevention and treat-
ment [7–13, 17–22]. Contrasting their success in stroke
prevention, PE and DVT the new generation oral antico-
agulants among patients after ACS were associated with a
dramatic increase in bleeding events. In the ACS trials
moderate reductions in the risk of stent thrombosis and
composite ischemic events were observed while regarding
effect on the frequency of MI the new generation oral
anticoagulant agents showed heterogeneous results [23].
The concern about an increased risk of MI was raised
first regarding dabigatran. This signal was present in the
first publication of the ‘‘randomized evaluation of long-
term anticoagulation therapy’’ (RE-LY) trial, there was a
Fig. 2 Impact of apixaban on the overall mortality. Subgroup analyses were performed according to the randomized medications applied in the
control groups
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higher incidence of MI with dabigatran (hazard ratio 1.38;
95 % CI 1.00–1.91; p\ 0.048) [19]. A subsequently per-
formed, repeated analysis suggested lack of significant
difference; however, was in contrasts with a meta-analysis
of seven trials of dabigatran that showed a significantly
higher risk of MI [4, 24, 25]. The underlying mechanisms
of this finding are not clear. As a member of the same class
ximelagatran was found to increase some proinflammatory
markers it has been hypothesized that dabigatran might
have effects that are unfavorable to atherosclerosis or
atherosclerotic thrombotic events [4]. Of note that the use
of ximelagatran resulted in reduction of MI events in the
ESTEEM trial conducted among patients with recent ACS
that makes the probability of a real class effect debatable
[26].
Rivaroxaban was the first available orally active direct
factor Xa inhibitor. In Europe and in the USA it was
approved for use in prevention of stroke and systemic
embolism, in patients with non-valvular atrial fibrillation
and for treatment of deep venous thromboembolism. It was
also approved for prevention of recurrent deep venous
thromboembolism and PE. Contrary to dabigatran, analysis
of the phase two and three trials showed reduction of MI
with rivaroxaban [3]. Of note, in patients after a reduced
dose (2.5 mg twice daily in combination with standard
antiplatelet therapy) of rivaroxaban resulted in reduction of
ischemic events as well as in improved survival in the anti-
Xa therapy to lower cardiovascular events in addition to
standard therapy in subjects with acute coronary syn-
drome–thrombolysis in myocardial infarction 46 (ATLAS
ACS 2–TIMI 51) trial compared to placebo [27]. Among
the new generation oral anticoagulants this was the only
phase three trial among ACS showing a statistically sig-
nificant benefit. As a possible explanation it has been
hypothesized that thrombin may have a dose dependent
balance among its anticoagulant and procoagulant action,
and at low dose rivaroxaban may more effectively affected
the latter. The facts, however, that among different doses of
rivaroxaban frequencies of ischemic and bleeding events
were parallel doubt this assumption and the reason for the
Fig. 3 Impact of apixaban on the frequency of major and clinically relevant non-major bleeding. Subgroup analyses were performed according
to the randomized medications applied in the control groups
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discrepancy remains unclear [27]. Based on the above data
rivaroxaban was approved in Europe but not in the USA in
patient after recent ACS.
Apixaban a direct factor Xa inhibitor has been available
in Europe since May 2011 and was approved for prevent-
ing venous thromboembolism after elective hip or knee
replacement. The FDA approved apixaban in december
2012 with an indication of reducing the risk of stroke and
systemic embolism in patients with non-valvular atrial
fibrillation. Unlike rivaroxaban, apixaban trials were not
successful in preventing ischemic events in patients after a
recent episode of ACS. Specifically the phase 3 ACS trial
[apixaban for prevention of acute ischemic events 2
(APPRAISE-2)] was prematurely stopped, owing to an
excess of clinically important bleeding events with apix-
aban in the absence of a counterbalancing reduction in
ischemic events [13]. The main duration of the follow-up
from the time of randomization was 240 in the apixaban
and 242 day in the placebo arm, compared to the planned
1.25 years, with a median exposure to the drug 175 days,
however, during this period 572 primary events were
encountered i.e. more than 60 % of the initially planned
number. Even if the increase in bleeding led more fre-
quently to discontinuation of the study drug and resulted in
the termination of the trial that limit the certainty of the
conclusions that can be drawn about efficacy the lack of
ischemic benefit raised serious concerns regarding the use
of apixaban together with antiplatelet drugs. In fact the
APPRAISE-2 trial did not show signal for increase in
coronary events but regarding the efficacy endpoints in this
trial apixaban reduced the rate of stent thrombosis from 1.3
to 0.9 % (OR 0.73 95 % CI 0.47–1.12) and the rate of MI
was also lower. (Fig. 1). Unfortunately, we lack trials
performed with low dose apixaban in patients with ACS.
This leaves the question unanswered as to whether low
dose treatment as with rivaroxaban would result in similar
improvement with apixaban.
It should be acknowledged that there might be specific
differences regarding the risk of MI altering with clinical
situations, and different control medications. Rate control
meta-regression analysis of the effect on MI frequency,
however, did not showed signal for such confounder
(Online resource 3). Moreover, the data were homogenous
across the different control groups, supporting the robust-
ness of the findings.
Some limitations to our analysis should be acknowl-
edged. In order to comprehensiveness we included phase
2, explorative and dose finding trials. Albeit these may
have introduced different risk and benefit effects in the
analysis the sensitivity analysis including only phase three
trials found similar results to that of the comprehensive
analysis. There was a 23 % of overlap between the patient
population of the AMPLIFY and the AMPLIFY-EXT
trials. To correct for this sensitivity analyses with exclu-
sion each of these trials were performed that do no
resulted in divergent results from the overall analysis.
(Table 3). Regarding the risk of MI, it very important to
note that most studies showed less than ten events per
Table 3 Sensitivity analyses
Odds ratio (95 % confidence interval)
Number of studies
(number of patients)
Myocardial
infarction
Cardiovascular
mortality
Overall
mortality
Fixed effect model 12 (54,054) 0.90 [0.77–1.05] 0.89 [0.77–1.02] 0.90 [0.82–0.98]*
Phase 3 trials 6 (50,728) 0.92 [0.78–1.07] 0.84 [0.68–1.05] 0.87 [0.73–1.03]
Phase 2 trials 4 (3,326) 0.64 [0.33–1.26] 1.33 [0.62–2.86] 1.29 [0.63–2.64]
AMPLIFY excluded 11 (48,659) 0.89 [0.77–1.04] 0.89 [0.73–1.08] 0.90 [0.76–1.06]
AMPLIFY-EXT excluded 11 (51,572) 0.90 [0.78–1.05] 0.91 [0.79–1.05] 0.90 [0.83–0.99]*
Non-valvular atrial fibrillation trials 3 (24,022) 0.87 [0.68–1.12] 0.88 [0.74–1.05] 0.87 [0.78–0.97]**
Acute coronary syndrome trials 3 (9,258) 0.88 [0.66–1.16] 0.99 [0.77–1.28] 1.1 [0.88–1.37]
Thrombosis prophylaxis after major
orthopedic surgery trials
4 (12,897) 1.18 [0.51–2.74] – 1.18 [0.47–2.96]
DVT or PE treatment trials 2 (7,877) 0.99 [0.32–3.02] 0.31 [0.13–0.71]** 0.60 [0.31–1.18]
Trials that excluding patients with APT 4 (12,897) 1.18 [0.51–2.74] No evaluated 1.21 [0.51–2.82]
Trials excluding patient with high dose ASA
([100 mg/day or[165 mg/day) or DAPT
4 (26,300) 0.88 [0.67–1.16] 0.52 [0.22–1.26] 0.87 [0.78–0.97]**
Trials not excluding patients with APT 4 (14,857) 0.89 [0.74–1.08] 0.94 [0.77–1.14] 0.95 [0.80–1.12]
Events during the follow up period excluded 12 (53,069) 0.90 [0.77–1.04] 0.88 [0.72–1.06] 0.89 [0.79–1.02]
ASA aspirin, APT antiplatelet therapy, DAPT dual antiplatelet therapy, DVT deep vein thrombosis, PE pulmonary embolism
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group representing a very low risk population. Most of
events were observed in only two studies: APRAISE-2
and ARISTOTLE. In addition the APRAISE-2 study has
been stopped early because of safety concern with apix-
aban. Hence, main limitation of our meta-analysis is that
none of the included trials had MI defined as primary
endpoint nor was adequately powered for this individual
end-point. Although we tried to achieve a comprehensive
overview of apixaban trials during the data capture three
trials (study of apixaban for the prevention of thrombosis-
related events in patients with acute medical illness
(ADOPT), a phase 2 pilot study of apixaban for the pre-
vention of thromboembolic events in patients with
advanced (metastatic) cancer and the Boticelli-DVT dose-
ranging study) had to be excluded because lack of
reporting the frequency of MI. In order to gain informa-
tion regarding the longest available follow-up in our
analysis events from the treatment periods and the follow-
up periods of the trials were included. Sensitivity analysis
with including events only during the treatment periods
showed no differences from the comprehensive analysis.
Also there are a number of studies with premature ter-
mination and short follow-up in this field. Consequently to
these limitations, results of the cumulative analysis may
not be regarded as definitive and can be interpreted only
as hypothesis generating data.
In conclusion meta-analysis of trials performed in a
broad spectrum of patients and compared against different
controls apixaban treatment was not associated with
increase of the rate of MI. Our current analysis extended
the earlier findings with reassuring the cardiovascular
safety of apixaban.
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